News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Tail-End of Swine Flu Helps GlaxoSmithKline Beat Forecasts
April 28, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Bumper sales of swine flu vaccine boosted GlaxoSmithKline's first-quarter earnings by 17 percent, more than expected, and the drugmaker reassured investors it could absorb the cost of U.S. healthcare reform.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
GSK
MORE ON THIS TOPIC
FDA
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
September 23, 2026
·
2 min read
·
Jef Akst
Manufacturing
Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030
September 22, 2026
·
2 min read
·
Nick Paul Taylor
IPO
2026 IPO blitz continues with 4 new biotech filings
September 22, 2026
·
4 min read
·
Tristan Manalac
Cancer
Boehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenics
September 22, 2026
·
2 min read
·
Tristan Manalac
